Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

Shares of DexCom Inc. DXCM rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for ...

The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this. Whatever happens, though ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked ...

Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

HCPs see CGM as the 'standard of care': Half of all HCPs felt CGM should be the standard of care for people with Type 2 diabetes whether they were using insulin to manage the condition or not. 96% of ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Dexcom, a medical device manufacturer that develops continuous glucose monitoring systems, received a warning letter from the FDA regarding manufacturing processes at its facilities in San Diego and ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...